AbbVie published the Q1 results of 2019, a decrease in the sales of Humira impacted the net sales, Imbruvica sales helping to maintain the revenues.
Time to find the next blockbuster as sales growth was reported to be 0.4% at the operational level.
AbbVie has reported sales of $7.828 billion, a decrease in 1.3 percent
Global sales of Humira was $4.446 billion, the sales were decreased by 5.6 percent on an operational basis. Internationally, net sales of Humira were reported to be $1.231 billion decreased 23 percent operationally because of the biosimilar competition.
Hematological oncology products were increased by $1.173 billion which is increased by 42.8 percent. Net revenues of Imbruvica were reported to be $1.022 billion, international profit sharing is $193 million. Venclexta sales were reported to be $151 million. Global HCV products sales were reported to be $815 million
Though AbbVie says to be an excellent start, all seems to be not well. Humira is losing its revenues, thanks for the biosimilars.
The sales in the United States increased by 7.1%, however, the global revenues of Humira was reduced by 23% because of biosimilars.
Imbruvica is expanding its therapeutic indications, with the recent approval from the US FDA for the treatment of adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Recently it got the approval of Skyrizi (risankizumab) for the treatment of plaque psoriasis. AbbVie is trying hard to retains its place in the area of autoimmune disorders with strong clinical evidence of upadacitinib.
